Investigating plasma volume expanders as novel macromolecular MRI-CEST contrast agents for tumor contrast-enhanced imaging.
chemical exchange saturation transfer
gadolinium
macromolecular agent
magnetic resonance imaging
plasma volume expander
Journal
Magnetic resonance in medicine
ISSN: 1522-2594
Titre abrégé: Magn Reson Med
Pays: United States
ID NLM: 8505245
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
26
02
2021
received:
22
06
2020
accepted:
01
03
2021
pubmed:
26
3
2021
medline:
21
5
2021
entrez:
25
3
2021
Statut:
ppublish
Résumé
The aim of this study was to investigate two clinically approved plasma volume expanders (dextran 70 and voluven) as macromolecular MRI-chemical exchange saturation transfer (CEST) contrast agents to assess tumor vascular properties. CEST contrast efficiency of both molecules (6% w/v) was measured in vitro at various irradiation saturation powers (1-6 μT for 5 s) and pH values (range, 5.5-7.9) and the exchange rate of hydroxyl protons was calculated. In vivo studies in a murine adenocarcinoma model (n = 4 mice for each contrast agent) upon i.v. injection provided CEST-derived perfusion tumor properties that were compared with those obtained with a gadolinium-based blood-pool agent (Gd-AAZTA-Madec). In vitro measurements showed a marked CEST contrast dependency to pH, with higher CEST contrast at lower pH values for both molecules. The measured prototropic exchange rates confirmed a base-catalyzed exchange rate that was faster for dextran 70 in comparison to voluven. Both molecules showed a similar CEST contrast increase (ΔST% > 3%) in the tumor tissue up to 30 min postinjection, with heterogeneous accumulation. In tumors receiving both CEST and T The obtained results showed that both voluven and dextran 70 can be exploited as MRI-CEST contrast agents for evaluating tumor enhancement properties. Their increased accumulation in tumors and prolonged contrast enhancement promote their use as blood-pool MRI-CEST agents to examine tumor vascularization.
Substances chimiques
Contrast Media
0
Plasma Substitutes
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
995-1007Informations de copyright
© 2021 International Society for Magnetic Resonance in Medicine.
Références
Farrugia A. Safety of plasma volume expanders. J Clin Pharmacol. 2011;51:292-300.
Hitosugi T, Saito T, Suzuki S, et al. Hydroxyethyl starch: the effect of molecular weight and degree of substitution on intravascular retention in vivo. Anesth Analg. 2007;105:724-728.
Dubniks M, Persson J, Grande PO. Comparison of the plasma volume-expanding effects of 6% dextran 70, 5% albumin, and 6% HES 130/0.4 after hemorrhage in the guinea pig. J Trauma. 2009;67:1200-1204.
Bunn F, Trivedi D. Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev. 2012:CD001319.
Bennett J, Basivireddy J, Kollar A, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. J Neuroimmunol. 2010;229:180-191.
Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. High and low molecular weight fluorescein isothiocyanate (FITC)-dextrans to assess blood-brain barrier disruption: technical considerations. Transl Stroke Res. 2011;2:106-111.
Pauty J, Usuba R, Takahashi H, et al. A vascular permeability assay using an in vitro human microvessel model mimicking the inflammatory condition. Nanotheranostics. 2017;1:103-113.
Dreher MR, Liu W, Michelich CR, Dewhirst MW, Yuan F, Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst. 2006;98:335-344.
Jo J, Lin X, Nakahara T, Aoki I, Saga T, Tabata Y. Preparation of polymer-based magnetic resonance imaging contrast agent to visualize therapeutic angiogenesis. Tissue Eng Part A. 2013;19:30-39.
Hifumi H, Yamaoka S, Tanimoto A, Citterio D, Suzuki K. Gadolinium-based hybrid nanoparticles as a positive MR contrast agent. J Am Chem Soc. 2006;128:15090-15091.
Zhang Z, He R, Yan K, et al. Synthesis and in vitro and in vivo evaluation of manganese(III) porphyrin-dextran as a novel MRI contrast agent. Bioorg Med Chem Lett. 2009;19:6675-6678.
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653-664.
Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71-79.
Miller MA, Gadde S, Pfirschke C, et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle. Sci Transl Med. 2015;7:314ra183.
Turetschek K, Preda A, Novikov V, et al. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging. 2004;20:138-144.
Gianolio E, Cabella C, Colombo Serra S, et al. B25716/1: a novel albumin-binding Gd-AAZTA MRI contrast agent with improved properties in tumor imaging. J Biol Inorg Chem. 2014;19:715-726.
Longo DL, Arena F, Consolino L, et al. Gd-AAZTA-MADEC, an improved blood pool agent for DCE-MRI studies on mice on 1 T scanners. Biomaterials. 2016;75:47-57.
Lauffer RB, Parmelee DJ, Dunham SU, et al. MS-325: Albumin-targeted contrast agent for MR angiography. Radiology. 1998;207:529-538.
La Noce A, Stoelben S, Scheffler K, et al. B22956/1, a new intravascular contrast agent for MRI: first administration to humans-preliminary results. Acad Radiol. 2002;9:S404-S406.
Henrotte V, Vander Elst L, Laurent S, Muller RN. Comprehensive investigation of the non-covalent binding of MRI contrast agents with human serum albumin. J Biol Inorg Chem. 2007;12:929-937.
Avedano S, Botta M, Haigh JS, Longo DL, Woods M. Coupling fast water exchange to slow molecular tumbling in Gd3+ chelates: why faster is not always better. Inorg Chem. 2013;52:8436-8450.
O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189-195.
Kiessling F, Morgenstern B, Zhang C. Contrast agents and applications to assess tumor angiogenesis in vivo by magnetic resonance imaging. Curr Med Chem. 2007;14:77-91.
Consolino L, Longo DL, Dastru W, et al. Functional imaging of the angiogenic switch in a transgenic mouse model of human breast cancer by dynamic contrast enhanced magnetic resonance imaging. Int J Cancer. 2016;139:404-413.
Longo DL, Dastru W, Consolino L, et al. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment. Magn Reson Imaging. 2015;33:725-736.
Plush SE, Woods M, Zhou YF, Kadali SB, Wong MS, Sherry AD. Nanoassembled capsules as delivery vehicles for large payloads of high relaxivity Gd3+ agents. J Am Chem Soc. 2009;131:15918-15923.
Ferrauto G, Di Gregorio E, Dastru W, Lanzardo S, Aime S. Gd-loaded-RBCs for the assessment of tumor vascular volume by contrast-enhanced-MRI. Biomaterials. 2015;58:82-92.
Botta M, Tei L. Relaxivity enhancement in macromolecular and nanosized GdIII-based MRI contrast agents. Eur J Inorg Chem. 2012;12:1945-1960.
Granato L, Longo D, Boutry S, et al. Synthesis and relaxometric characterization of new Poly[N, N-bis(3-aminopropyl)glycine] (PAPGly) Dendrons Gd-based contrast agents and their in vivo study by using the dynamic contrast-enhanced MRI technique at low field (1 T). Chem Biodivers. 2019;16:e1900322.
Pereira MIA, Pereira G, Monteiro CAP, et al. Hydrophilic quantum dots functionalized with Gd(III)-DO3A monoamide chelates as bright and effective T-1-weighted bimodal nanoprobes. Sci Rep-Uk. 2019;9:2341.
Pinho SLC, Sereno J, Abrunhosa AJ, et al. Gd- and Eu-loaded iron Oxide@Silica Core-shell nanocomposites as trimodal contrast agents for magnetic resonance imaging and optical imaging. Inorg Chem. 2019;58:16618-16628.
Garello F, Gunduz S, Vibhute S, Angelovski G, Terreno E. Dendrimeric calcium-sensitive MRI probes: the first low-field relaxometric study. J Mater Chem B. 2020;8:969-979.
Angelovski G. Heading toward macromolecular and nanosized bioresponsive MRI probes for successful functional imaging. Acc Chem Res. 2017;50:2215-2224.
McMahon MT, Bulte JWM. Two decades of dendrimers as versatile MRI agents: a tale with and without metals. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018;10:e1496.
Quattrocchi CC, Mallio CA, Errante Y, et al. Gadodiamide and dentate nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol. 2015;50:470-472.
Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology. 2014;270:834-841.
Liu G, Song X, Chan KW, McMahon MT. Nuts and bolts of chemical exchange saturation transfer MRI. NMR Biomed. 2013;26:810-828.
Longo DL, Michelotti F, Consolino L, et al. In vitro and in vivo assessment of nonionic iodinated radiographic molecules as chemical exchange saturation transfer magnetic resonance imaging tumor perfusion agents. Invest Radiol. 2016;51:155-162.
Anemone A, Consolino L, Longo DL. MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. Eur Radiol. 2017;27:2170-2179.
Aime S, Delli Castelli D, Lawson D, Terreno E. Gd-loaded liposomes as T1, susceptibility, and CEST agents, all in one. J Am Chem Soc. 2007;129:2430-2431.
Lesniak WG, Oskolkov N, Song X, et al. Salicylic acid conjugated dendrimers are a tunable, high performance CEST MRI NanoPlatform. Nano Lett. 2016;16:2248-2253.
Castelli DD, Terreno E, Longo D, Aime S. Nanoparticle-based chemical exchange saturation transfer (CEST) agents. NMR Biomed. 2013;26:839-849.
Wu Y, Zhou Y, Ouari O, et al. Polymeric PARACEST agents for enhancing MRI contrast sensitivity. J Am Chem Soc. 2008;130:13854-13855.
Ali MM, Woods M, Suh EH, et al. Albumin-binding PARACEST agents. J Biol Inorg Chem. 2007;12:855-865.
Farashishiko A, Slack JR, Botta M, Woods M. ParaCEST agents encapsulated in reverse nano-assembled capsules (RACs): how slow molecular tumbling can quench CEST contrast. Front Chem. 2018;6:96.
Zhao JM, Har-el YE, McMahon MT, et al. Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes. J Am Chem Soc. 2008;130:5178-5184.
Xu X, Chan KW, Knutsson L, et al. Dynamic glucose enhanced (DGE) MRI for combined imaging of blood-brain barrier break down and increased blood volume in brain cancer. Magn Reson Med. 2015;74:1556-1563.
Song X, Walczak P, He X, et al. Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion. J Cereb Blood Flow Metab. 2016;36:1186-1194.
Longo DL, Moustaghfir FZ, Zerbo A, et al. EXCI-CEST: exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging. Int J Pharm. 2017;525:275-281.
Rivlin M, Tsarfaty I, Navon G. Functional molecular imaging of tumors by chemical exchange saturation transfer MRI of 3-O-Methyl-D-glucose. Magn Reson Med. 2014;72:1375-1380.
Nasrallah FA, Pages G, Kuchel PW, Golay X, Chuang KH. Imaging brain deoxyglucose uptake and metabolism by glucoCEST MRI. J Cereb Blood Flow Metab. 2013;33:1270-1278.
Han Z, Liu GS. Sugar-based biopolymers as novel imaging agents for molecular magnetic resonance imaging. Wires Nanomed Nanobi. 2019;11:e1551.
Consolino L, Anemone A, Capozza M, et al. Non-invasive investigation of tumor metabolism and acidosis by MRI-CEST imaging. Front Oncol. 2020;10:161.
Li Y, Qiao Y, Chen H, et al. Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med. 2018;79:1001-1009.
Zaiss M, Angelovski G, Demetriou E, McMahon MT, Golay X, Scheffler K. QUESP and QUEST revisited-fast and accurate quantitative CEST experiments. Magn Reson Med. 2018;79:1708-1721.
Zaiss M, Anemone A, Goerke S, et al. Quantification of hydroxyl exchange of D-Glucose at physiological conditions for optimization of glucoCEST MRI at 3, 7 and 9.4 Tesla. NMR Biomed. 2019;32:e4113.
Sun PZ. Simplified and scalable numerical solution for describing multi-pool chemical exchange saturation transfer (CEST) MRI contrast. J Magn Reson. 2010;205:235-241.
Hills BP. Multinuclear NMR studies of water in solutions of simple carbohydrates. Mol Phys. 1991;72:1099-1121.
Terreno E, Stancanello J, Longo D, et al. Methods for an improved detection of the MRI-CEST effect. Contrast Media Mol Imaging. 2009;4:237-247.
Dilauro M, Quon M, McInnes MD, et al. Comparison of contrast-enhanced multiphase renal protocol CT versus MRI for diagnosis of papillary renal cell carcinoma. AJR Am J Roentgenol. 2016;206:319-325.
Anemone A, Consolino L, Longo DL. MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. Eur Radiol. 2017;27:2170-2179.
Wang SC, Wikstrom MG, White DL, et al. Evaluation of Gd-DTPA-labeled dextran as an intravascular MR contrast agent: imaging characteristics in normal rat tissues. Radiology. 1990;175:483-488.
Wittgren B, Wahlund K-G, Andersson M, Arfvidsson C. Polysaccharide characterization by flow field-flow fractionation-multiangle light scattering: initial studies of modified starches. Int J Polym Anal Charact. 2002;7:19-40.
Affram K, Smith T, Helsper S, et al. Comparative study on contrast enhancement of Magnevist and Magnevist-loaded nanoparticles in pancreatic cancer PDX model monitored by MRI. Cancer Nanotechnol. 2020;11:5.
Mi P, Cabral H, Kokuryo D, et al. Gd-DTPA-loaded polymer-metal complex micelles with high relaxivity for MR cancer imaging. Biomaterials. 2013;34:492-500.
Wen S, Zhao Q, An X, et al. Multifunctional PEGylated multiwalled carbon nanotubes for enhanced blood pool and tumor MR imaging. Adv Healthc Mater. 2014;3:1568-1577, 1525.
Reeves KJ, Brookes ZL, Reed MW, Brown NJ. Evaluation of fluorescent plasma markers for in vivo microscopy of the microcirculation. J Vasc Res. 2012;49:132-143.
Botta M, Avedano S, Giovenzana GB, et al. Relaxometric study of a series of Monoaqua Gd-III complexes of rigidified EGTA-like chelators and their noncovalent interaction with human serum albumin. Eur J Inorg Chem. 2011;6:802-810.
Nakamura Y, Mochida A, Choyke PL, Kobayashi H. Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem. 2016;27:2225-2238.
Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res. 1988;48:7022-7032.
Tan J, Shah S, Thomas A, Ou-Yang HD, Liu Y. The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid Nanofluid. 2013;14:77-87.
Vercueil A, Grocott MP, Mythen MG. Physiology, pharmacology, and rationale for colloid administration for the maintenance of effective hemodynamic stability in critically ill patients. Transfus Med Rev. 2005;19:93-109.
Waitzinger J, Bepperling F, Pabst G, Opitz J. Hydroxyethyl starch (HES) [130/0.4], a new HES specification: pharmacokinetics and safety after multiple infusions of 10% solution in healthy volunteers. Drugs in R&D. 2003;4:149-157.
Chen H, Liu D, Li Y, et al. CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. Magn Reson Med. 2019;82:1471-1479.